Table 4.

Summary of renal outcomes following different EPT in primary FSGS.

Patients (n)	Responders, n/total (%)	CR, n/total (%)	PR, n/total (%)	Follow up duration
PE (31)	20/31 (65) Long-term 15/31 (48)a			14.4 ± 6.8 months in 5 case report studies [22,23,25,28,29] 29 ± 4 months in a case series study [18] 27.5 ± 6.3 months in a case series study [17] 17 months (IQR 15, 20) in a case series study [31]
Non-HD (30)	19/30 (63)	8/30 (27)	11/30 (37)
HD (1)	1/1 (100)
LDL-A (61)	33/61 (54) Long-term 12/28 (43)			3 weeks, 3 months and 4 months in 3 case report studies, respectively [21,26,27] 2 week, 4 weeks and 2 years in 3 case series studies, respectively [30,34,35]
Non-HD (59)	31/59 (53)	12/29 (41)b	1/29 (3)b
HD (2)	2/2 (100)
IA (10)c	4/10 (40) Long-term ¼ (25)	0/10 (0)	4/10 (40)	25 weeks and 6 months in 2 patients, respectively [32] NA in 7 patients
LCAP (2)c	1/2 (50) Long-term 1/2 (50)	1/2 (50)		47 and 40 months, respectively [36]

EPT: extracorporeal plasma therapy; FSGS: focal segmental glomerulosclerosis; CR: complete remission; PR: partial remission; IQR: interquartile (25% and 75% percentile); PE: plasmapheresis or plasma exchange using albumin; HD: hemodialysis; LDL-A: LDL apheresis using dextran sulfate cellulose column; IA: immunoadsorption using protein A or IgG; NA: not available; LCAP: lymphocytapheresis using Cellsorba, a leukapheresis filter.

^aLong-term indicates follow-up duration is ≥6 months. ^bNA in 2 case series studies (n = 7 and 23, respectively). Remission and effectiveness were reported in the 2 studies [30,35]. ^cThe two patients are non-hemodialysis.